<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240808</url>
  </required_header>
  <id_info>
    <org_study_id>19-2807</org_study_id>
    <nct_id>NCT04240808</nct_id>
  </id_info>
  <brief_title>Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)</brief_title>
  <official_title>Phase I Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether immune cells modified to recognize B-cell non-Hodgkin lymphoma&#xD;
      (NHL) can be successfully manufactured at the University of Colorado Anschutz and whether&#xD;
      these cells can be administered with an acceptable safety profile. Adults who have been&#xD;
      diagnosed with B-cell non-Hodgkin lymphoma (NHL) that has relapsed or no longer responds to&#xD;
      chemotherapy (relapsed or refractory) may be eligible to participate in this study.&#xD;
&#xD;
      The investigators will use participants own immune cells, called T cells, to kill the&#xD;
      lymphoma. These T cells are involved in fighting infections and in some cases, can also kill&#xD;
      cancer cells. The investigators will extract T cells from the participant's blood, modify the&#xD;
      cells in a laboratory, and then return teh cells to the participant's body via intravenous&#xD;
      (IV) injection. In the laboratory, the investigators will add a new gene into the T cells&#xD;
      that allows the T cells to recognize and kill the lymphoma cells, and allows these modified&#xD;
      cells to multiply and increase in numbers. To put the new gene into your T cells, the&#xD;
      investigators will use a weakened virus. The virus is modified so that it cannot multiply or&#xD;
      spread once the cells are infused.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this Phase 1 open-label study is to assess the feasibility of UCD19 Chimeric&#xD;
      Antigen Receptor (CAR) T Cells manufacture onsite, successful infusion of eligible subjects,&#xD;
      and safety of UCD19 CAR T Cells infusion in subjects with relapsed/refractory B-Cell&#xD;
      Non-Hodgkin's Lymphoma (B-NHL).&#xD;
&#xD;
      Six (6) subjects will participate in the initial cohort of this open-label, single arm,&#xD;
      single site study to assess dose-limiting toxicity (DLT) and safety; the first set of 3&#xD;
      subjects will initiate treatment with lymphodepleting chemotherapy prior to CAR T cell&#xD;
      infusion staggered 30 days from CAR T cell dosing of the previously treated subject.&#xD;
      Depending on the assessment of DLTs, the second set of 3 subjects may be enrolled and dosed&#xD;
      without stagger.&#xD;
&#xD;
      After the initial 6 subjects have received treatment, an additional 14 subjects will&#xD;
      participate in the Phase 1 expansion study.&#xD;
&#xD;
      Participants will include adults with relapsed/ primary refractory CD19 positive (i.e. CD19&#xD;
      expressing) B-NHL as confirmed by either flow cytometry, immunohistochemistry (IHC), or both&#xD;
      who are not candidates for other curative forms of therapy. Enrolled participants will&#xD;
      receive lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral&#xD;
      Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes). Participants will be&#xD;
      enrolled up to 1 month before anticipated date of apheresis, and will be considered completed&#xD;
      at 12 months post-treatment.&#xD;
&#xD;
      Long Term Follow Up will be conducted under a separate protocol and will occur for up to 15&#xD;
      Years to collect data on the long-term safety of UCD19 CAR T Cells, and for the observation,&#xD;
      detection, and evaluation of latent adverse reactions including secondary malignancies.&#xD;
&#xD;
      While this study focuses on primary endpoints for feasibility of the manufacturing and&#xD;
      infusion processes and safety of the administered UCD19 CAR T Cells, preliminary evidence of&#xD;
      effectiveness will be collected and analyzed for use in planning future CAR T cell therapy&#xD;
      studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility: Successful manufacture of UCD19 CAR T Cells, as determined by the number of successfully manufactured doses</measure>
    <time_frame>Day 0 (infusion)</time_frame>
    <description>The successful manufacture of UCD19 Chimeric Antigen Receptor (CAR) T Cells onsite meeting the IND-defined release criteria. Manufacture of UCD19 CAR T Cells will begin after enrollment and be completed within 1 month. Success will be determined by whether or not the participant's CAR T Cell count meets the target dose required for infusion at Day 0. The number of successfully manufactured doses will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Percent of Participants successfully infused with UCD19 CAR T Cells</measure>
    <time_frame>Day 0 (infusion)</time_frame>
    <description>The percent of participants who are able to receive an infusion of UCD19 CAR T cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Number of Participants Who Experience a Dose Limiting Toxicity (DLT) within 30 days after treatment</measure>
    <time_frame>Up to 30 Days Post-Infusion</time_frame>
    <description>The number of subjects who receive UCD19 CAR T Cells and experience a DLT within 30 days after treatment, as defined herein using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE v5.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Percent of Participants Who Experience a Dose Limiting Toxicity (DLT) within 30 days after treatment</measure>
    <time_frame>Up to 30 Days Post-Infusion</time_frame>
    <description>The percent of all subjects who receive UCD19 CAR T Cells and experience a DLT within 30 days after treatment, as defined herein using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE v5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall response rate (Complete Response (CR)/Partial Response (PR)/Stable Disease (SD)) at 90 days</measure>
    <time_frame>90 Days Post-Infusion</time_frame>
    <description>The number of participants with Complete Response (CR)/Partial Response (PR)/Stable Disease (SD) at 90 days post-treatment, as determined by the investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall response rate (Complete Response (CR)/Partial Response (PR)/Stable Disease (SD)) at 6 Months</measure>
    <time_frame>6 Months Post-Infusion</time_frame>
    <description>The number of participants with Complete Response (CR)/Partial Response (PR)/Stable Disease (SD) at 6 months post-treatment, as determined by the investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall response rate (Complete Response (CR)/Partial Response (PR)/Stable Disease (SD)) at 1 Year</measure>
    <time_frame>1 Year Post-Infusion</time_frame>
    <description>The number of participants with Complete Response (CR)/Partial Response (PR)/Stable Disease (SD) at 1 Year post-treatment, as determined by the investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Rate of participants with Complete Response at 6 Months</measure>
    <time_frame>6 Months Post-Infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Rate of participants with Complete Response at 1 Year</measure>
    <time_frame>1 Year Post-Infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Median Duration of Remission at 1 Year</measure>
    <time_frame>1 Year Post-Infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Progression Free Survival (PFS) at 1 Year</measure>
    <time_frame>1 Year Post-Infusion</time_frame>
    <description>Number of participants with Progression Free Survival (PFS) at 1 year post-infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall Survival (OS) at 1 Year</measure>
    <time_frame>1 Year Post-Infusion</time_frame>
    <description>Number of participants surviving at 1 year post-infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>UCD19 CAR T Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCD19 CAR T Cells</intervention_name>
    <description>Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes)</description>
    <arm_group_label>UCD19 CAR T Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated Informed Consent form.&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the parent study and the long-term follow-up observational study.&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating females, aged 18 to 80 years.&#xD;
&#xD;
          -  Performance status according to the Eastern Cooperative Oncology Group â‰¤ 2.&#xD;
&#xD;
          -  Failed two or more lines of systemic therapy.&#xD;
&#xD;
          -  Unable to receive commercially available CD19 CAR T Cells.&#xD;
&#xD;
          -  Relapsed or primary refractory CD19 positive (i.e. CD19 expressing) B-NHL of the&#xD;
             following types as confirmed by either flow cytometry, Immunohistochemistry (IHC), or&#xD;
             both:&#xD;
&#xD;
               -  Diffuse large B-cell lymphoma (DLBCL)&#xD;
&#xD;
               -  Burkitt lymphoma&#xD;
&#xD;
               -  Intermediate lymphoma between Burkitt and DLBCL&#xD;
&#xD;
               -  Primary Mediastinal B-cell lymphoma (PMBL)&#xD;
&#xD;
               -  Follicular lymphoma&#xD;
&#xD;
               -  Mantle cell lymphoma (MCL)&#xD;
&#xD;
               -  Marginal zone lymphoma (MZL)&#xD;
&#xD;
          -  No available curative alternative treatment, as determined by primary treating&#xD;
             oncologist.&#xD;
&#xD;
          -  No active Graft-versus-Host Disease (GvHD).&#xD;
&#xD;
          -  In women of childbearing potential, willingness to use effective means of birth&#xD;
             control for 1 year after UCD19 CAR T Cell infusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapies:&#xD;
&#xD;
               -  Received monoclonal antibody therapy within 14 days of the apheresis; or&#xD;
&#xD;
               -  Received immunomodulatory drugs (lenalidomide, tyrosine kinase inhibitors) within&#xD;
                  14 days of the apheresis; or&#xD;
&#xD;
               -  Received corticosteroids more than 7.5mg/day within 14 days of the apheresis&#xD;
                  (physiologic replacement allowed up until apheresis, as clinically indicated); or&#xD;
&#xD;
               -  Allogeneic hematopoietic stem cell transplant with 90 days (immunosuppressive&#xD;
                  therapy for at least 4 weeks) of apheresis; or&#xD;
&#xD;
               -  Donor lymphocyte infusion within 4 weeks of apheresis.&#xD;
&#xD;
               -  Cluster of differentiation 3 (CD3) count &lt;0.15 x 106 cells/mL&#xD;
&#xD;
          -  Severe psychiatric illness that could impede the patient's ability to provide informed&#xD;
             consent and/or adhere to the parent protocol and/or the long-term follow-up protocol.&#xD;
&#xD;
          -  Active HIV (Acquired Immune Deficiency Syndrome) or history of HIV infection, as&#xD;
             directed by schedule or if known.&#xD;
&#xD;
          -  Active Hepatitis B or Hepatitis C infection.&#xD;
&#xD;
          -  Diffusion capacity of the lungs for carbon monoxide &lt; 40% predicted prior to&#xD;
             lymphodepletion.&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 40% (evaluated by echocardiogram [ECHO] or&#xD;
             Multigated Acquisition Scan [MUGA]) prior to lymphodepletion.&#xD;
&#xD;
          -  Transaminases &gt; 5x upper limit of normal prior to lymphodepletion.&#xD;
&#xD;
          -  Serum Bilirubin &gt; 4 mg/dL prior to lymphodepletion.&#xD;
&#xD;
          -  Serum Creatinine &gt; 1.6 mg/dL or measured creatinine clearance &lt; 50 mL/min prior to&#xD;
             lymphodepletion.&#xD;
&#xD;
          -  Active infection that is unresponsive to antimicrobial therapy prior to&#xD;
             lymphodepletion.&#xD;
&#xD;
          -  Females planning to become pregnant during the course of the study.&#xD;
&#xD;
          -  Unwillingness or inability to comply with study visits and study procedures for the&#xD;
             entire duration of study participation.&#xD;
&#xD;
          -  Unsuitable for cellular therapy for any reason, in the opinion of the Investigator.&#xD;
&#xD;
          -  Any prior gene therapy, including prior CAR T cell therapy.&#xD;
&#xD;
          -  Active central nervous system (CNS) disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Verneris, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado Denver, Anschutz Medical Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manali Kamdar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Denver, Anschutz Medical Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chanel Mansfield, MPH</last_name>
    <phone>303-724-5722</phone>
    <email>chanel.mansfield@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Schatz</last_name>
      <phone>720-848-0628</phone>
      <email>DEREK.SCHATZ@CUANSCHUTZ.EDU</email>
    </contact>
    <investigator>
      <last_name>Manali Kamdar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Car T</keyword>
  <keyword>Car T Cells</keyword>
  <keyword>Cancer</keyword>
  <keyword>B-Cell Non-Hodgkin's Lymphoma</keyword>
  <keyword>B-NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

